-+ 0.00%
-+ 0.00%
-+ 0.00%

Dr Reddy’s gets four USFDA observations at Bachupally formulations plant after GMP inspection

PUBT·08/17/2026 10:41:54
Listen to the news
Dr Reddy’s gets four USFDA observations at Bachupally formulations plant after GMP inspection
  • USFDA completed a GMP inspection at Dr. Reddy’s Bachupally (FTO-3) formulations plant in Hyderabad on Aug. 6-14, 2026.
  • FDA issued a Form 483 with four observations, raising potential compliance risk for the site’s manufacturing operations.
  • The company plans to respond within the stipulated timeline.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dr. Reddy's Laboratories Limited published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001575872-26-000583), on August 17, 2026, and is solely responsible for the information contained therein.